39581-55-0

Usage

Uses

Used in Pharmaceutical Synthesis:
5-Methoxy-benzofuran-3-one is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic benefits.
Used in Organic Chemistry:
As a building block in organic chemistry, 5-Methoxy-benzofuran-3-one is utilized for its structural properties to create a wide range of organic compounds, enhancing the diversity of chemical products.
Used in Medicinal Chemistry Research:
5-Methoxy-benzofuran-3-one is employed as a subject of study in medicinal chemistry to explore its pharmacological properties and potential applications in the treatment of various diseases and conditions.
Used in Drug Design and Development:
In the field of drug design and development, 5-Methoxy-benzofuran-3-one serves as a valuable compound for the creation of novel drug candidates, potentially leading to breakthroughs in therapeutic interventions.

InChI:InChI=1/C9H8O3/c1-11-6-2-3-9-7(4-6)8(10)5-12-9/h2-4H,5H2,1H3

Upstream product

• 75717-53-2 2-chloro-1-(2-hydroxy-5-methoxyphenyl)ethan-1-one 
• 203524-87-2 1-(2-hydroxy-5-methoxyphenyl)-2-bromoethanone 
• 672-13-9 2-hydroxy-5-methoxybenzaldehyde 
• 99299-73-7 2-ethynyl-4-methoxyphenol 
• 796851-92-8 methyl 2-((ethoxycarbonyl)methoxy)-5-methoxybenzoate 
• 104796-21-6 methyl 5-methoxy-2-(2-methoxy-2-oxoethoxy)benzoate 
• 2612-02-4 5-methoxysalicylic acid 
• 2905-82-0 methyl 5-methoxy-2-hydroxybenzoate 
• 1204-22-4 2-chloro-1-(2,5-dimethoxy-phenyl)-ethanone 
• 150-78-7 1,4-dimethoxybezene 
• 107-14-2 chloroacetonitrile 
• 150-76-5 4-methoxy-phenol 
• 60770-33-4 5-methoxybenzofuran-3-yl acetate 
• 1877-75-4 2-(4-methoxyphenoxy)acetic acid 

Downstream Products

• 13391-28-1 5-methoxybenzofuran 
• 118610-60-9 methyl 2-(5-methoxybenzofuran-3-yl)acetate 
• 38216-55-6 5-methoxy-3-oxo-2-phenylmethylidene-2,3-dihydrobenzo[b]furan 
• 99385-88-3 5-hydroxy-2,3-dihydrobenzofuran-6-carboxaldehyde 
• 99355-75-6 5-methoxy-2,3-dihydrobenzofuran-6-carboxaldehyde 
• 99385-65-6 N-phenyl-6-(aminomethyl)-5-hydroxy-2,3-dihydrobenzofuran 
• 99385-89-4 N-phenyl-6-(iminomethyl)-5-hydroxy-2,3-dihydrobenzofuran 
• 99385-92-9 6-<<(4-acetylphenyl)imino>methyl>-5-hydroxy-2,3-dihydrobenzofuran 
• 99385-66-7 N-<2-(hydroxymethyl)phenyl>-6-(aminomethyl)-5-hydroxy-2,3-dihydrobenzofuran 
• 99385-90-7 6-<<<2-(hydroxymethyl)phenyl>imino>methyl>-5-hydroxy-2,3-dihydrobenzofuran 
• 99385-67-8 N-(2,4-difluorophenyl)-6-(aminomethyl)-5-hydroxy-2,3-dihydrobenzofuran 
• 99385-91-8 6-{[(E)-2,4-Difluoro-phenylimino]-methyl}-2,3-dihydro-benzofuran-5-ol 

Relevant academic research and scientific papers

Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer

Evodiamine (Evo) is a quinazolinocarboline alkaloid found in Evodia rutaecarpa and exhibits moderate antiproliferative activity. Herein, we report using a scaffold-hopping approach to identify a series of novel polycyclic heterocyclic derivatives based on Evo as the topoisomerase I (Top1) inhibitor for the treatment of triple-negative breast cancer (TNBC), which is an aggressive subtype of breast cancer with limited treatment options. The most potent compound 7f inhibited cell growth in a human breast carcinoma cell line (MDA-MB-231) with an IC50 value of 0.36 μM. Further studies revealed that Top1 was the target of 7f, which directly induced irreversible Top1-DNA covalent complex formation or induced an oxidative DNA lesion through an indirect mechanism mediated by reactive oxygen species. More importantly, in vivo studies showed that 7f exhibited potent antitumor activity in a TNBC-patient-derived tumor xenograft model. These results suggest that compound 7f deserves further investigation as a promising candidate for the treatment of TNBC.

A Hg(OTf)2-Catalyzed Enolate Umpolung Reaction Enables the Synthesis of Coumaran-3-ones and Indolin-3-ones

The potential of mercury catalysis has been extended to the arena of enolate umpolung reactions for the first time by the generation of enolonium species via Hg(OTf)2-catalyzed N-oxide addition to alkynes. The enolonium species formed can undergo intramolecular nucleophilic attack by hydroxyl or amino groups, leading to the synthesis of various coumaran-3-ones and indolin-3-ones.

Virtual screening-driven discovery of dual 5-HT6/5-HT2A receptor ligands with pro-cognitive properties

A virtual screening campaign aimed at finding structurally new compounds active at 5-HT6R provided a set of candidates. Among those, one structure, 4-(5-{[(2-{5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl}ethyl)amino]methyl}furan-2-yl)phenol (1, 5-HT6R Ki = 91 nM), was selected as a hit for further optimization. As expected, the chemical scaffold of selected compound was significantly different from all the serotonin receptor ligands published to date. Synthetic efforts, supported by molecular modelling, provided 43 compounds representing different substitution patterns. The derivative 42, 4-(5-{[(2-{5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl}ethyl)amino]methyl}furan-2-yl)phenol (5-HT6R Ki = 25, 5-HT2AR Ki = 32 nM), was selected as a lead and showed a good brain/plasma concentration profile, and it reversed phencyclidine-induced memory impairment. Considering the unique activity profile, the obtained series might be a good starting point for the development of a novel antipsychotic or antidepressant with pro-cognitive properties.

Microwave-Assisted Synthesis of Benzofuran-3(2H)-ones

A new method for the synthesis of benzofuran-3(2H)-ones under microwave conditions was developed. The reaction conditions were screened, and the scope of benzoate substrates was investigated. The results showed that our method could provide rapid access to these important dihydrobenzofuranones in 43% to 58% yields.

Discovery of benzofuran-3(2H)-one derivatives as novel DRAK2 inhibitors that protect islet β-cells from apoptosis

Death-associated protein kinase-related apoptosis-inducing kinase-2 (DRAK2) is a serine/threonine kinase that plays a key role in a wide variety of cell death signaling pathways. Inhibition of DRAK2 was found to efficiently protect islet β-cells from apoptosis and hence DRAK2 inhibitors represent a promising therapeutic strategy for the treatment of diabetes. Only very few chemical entities targeting DRAK2 are currently known. We carried out a high throughput screening and identified compound 4 as a moderate DRAK2 inhibitor with an IC50value of 3.15?μM. Subsequent SAR studies of hit compound 4 led to the development of novel benzofuran-3(2H)-one series of DRAK2 inhibitors with improved potency and favorable selectivity profiles against 26 selected kinases. Importantly, most potent compounds 40 (IC50?=?0.33?μM) and 41 (IC50?=?0.25?μM) were found to protect islet β-cells from apoptosis in dose-dependent manners. These data support the notion that small molecule inhibitors of DRAK2 represents a promising strategy for the treatment of diabetes.

Novel evodiamine derivatives as well as preparation method and application of novel evodiamine derivatives

The invention relates to the field of medicinal chemistry and particularly relates to novel evodiamine derivatives and also discloses a preparation method of the novel evodiamine derivatives and an application of the novel evodiamine derivatives to treatm

OPIOID RECEPTOR MODULATORS

The present invention provides a compound having the structure wherein A is a ring structure, with or without substitution; X1 is C or N; X2 is N, 0, or S; Y1 is H, -(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alky

NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS

Novel tricyclic compounds of Formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing osteoporosis and similar conditions. The compounds are effective as calcium sensing receptor antagonists. Pharmaceutical compositions and methods of treatment are also included.

NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OSTEOPOROSIS

Novel tricyclic compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing osteoporosis and similar conditions. The compounds are effective as calcium sensing receptor antagonists. Pharmaceutical compositions and methods of treatment are also included.

99mTc/Re complexes based on flavone and aurone as SPECT probes for imaging cerebral β-amyloid plaques

Two 99mTc/Re complexes based on flavone and aurone were tested as potential probes for imaging β-amyloid plaques using single photon emission computed tomography. Both 99mTc-labeled derivatives showed higher affinity for Aβ(1-42) aggregates than did 99mTc-BAT. In sections of brain tissue from an animal model of AD, the Re-flavone derivative 9 and Re-aurone derivative 19 intensely stained β-amyloid plaques. In biodistribution experiments using normal mice, 99mTc-labeled flavone and aurone displayed similar radioactivity pharmacokinetics. With additional modifications to improve their brain uptake, 99mTc complexes based on the flavone or aurone scaffold may serve as probes for imaging cerebral β-amyloid plaques.